Cargando…

Therapeutic targeting of TRAIL death receptors

The discovery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) along with its potent and selective antitumor effects initiated a decades-long search for therapeutic strategies to target the TRAIL pathway. First-generation approaches were focused on the development of TRAIL receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Cristofano, Francesca, George, Andrew, Tajiknia, Vida, Ghandali, Maryam, Wu, Laura, Zhang, Yiqun, Srinivasan, Praveen, Strandberg, Jillian, Hahn, Marina, Sanchez Sevilla Uruchurtu, Ashley, Seyhan, Attila A., Carneiro, Benedito A., Zhou, Lanlan, Huntington, Kelsey E., El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2023
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988005/ https://www.ncbi.nlm.nih.gov/pubmed/36629496 http://dx.doi.org/10.1042/BST20220098

Ejemplares similares

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs
por: Huntington, Kelsey E., et al.
Publicado: (2021)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Targeting the Integrated Stress Response in Cancer Therapy
por: Tian, Xiaobing, et al.
Publicado: (2021)

Regulation of the human TRAIL gene
por: Allen, Joshua E., et al.
Publicado: (2012)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
por: Louie, Anna D., et al.
Publicado: (2021)

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
por: Raufi, Alexander G., et al.
Publicado: (2023)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches
por: Badie, Fereshteh, et al.
Publicado: (2021)

Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity
por: Huntington, Kelsey E., et al.
Publicado: (2022)

Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity
por: Huntington, Kelsey E., et al.
Publicado: (2022)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

An Update on the Effects of Probiotics on Gastrointestinal Cancers
por: Davoodvandi, Amirhossein, et al.
Publicado: (2021)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2
por: Huntington, Kelsey E, et al.
Publicado: (2021)

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients with COVID-19
por: Huntington, Kelsey E., et al.
Publicado: (2020)

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
por: Jhaveri, Aakash V., et al.
Publicado: (2021)

HGG-42. PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY
por: Borsuk, Robyn, et al.
Publicado: (2021)

DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Borsuk, Robyn, et al.
Publicado: (2020)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
por: De Souza, Andre, et al.
Publicado: (2020)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

Investing in biomedical research is important
por: El-Deiry, Wafik S
Publicado: (2013)

Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy
por: El-Deiry, Wafik S
Publicado: (2013)

Are we losing the war on cancer?
por: El-Deiry, Wafik S
Publicado: (2013)

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells
por: Zhou, Lanlan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvvqt33j45fbg14snl8urus79i